Last reviewed · How we verify
Afluria Quad
Afluria Quad is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus.
Afluria Quad is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Afluria Quad |
|---|---|
| Sponsor | Osivax |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
The vaccine contains inactivated (killed) virus particles or viral antigens from four influenza strains (two A subtypes and two B lineages), which are administered intramuscularly to induce both humoral and cellular immune responses. This approach helps the immune system recognize and mount a protective response against circulating influenza viruses during the flu season.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Afluria Quad CI brief — competitive landscape report
- Afluria Quad updates RSS · CI watch RSS
- Osivax portfolio CI